We are proud to share that the Faculty of Medicine Siriraj Hospital, Mahidol University, has signed a Memorandum of Understanding (MOU) with Novo Nordisk Pharma (Thailand) Ltd. This partnership focuses on advancing research in diabetes, obesity, and other rare diseases. Our collaboration aims to enhance clinical research opportunities, foster innovative approaches, and improve patient care by involving them in cutting-edge clinical trials.
The signing ceremony, held on August 27, 2024, was honored by the presence of Prof. Apichat Asavamongkolkul, Dean of the Faculty of Medicine Siriraj Hospital, and Mr. Enrico Cañal Bruland, Vice President and General Manager of Novo Nordisk Pharma (Thailand) Ltd., along with distinguished faculty members and executives from both organizations.
We also hosted a seminar titled “State-of-the-Art Transformations in Diabetes and Obesity Management,” where leading experts shared insights on the latest innovations and treatment strategies. The event concluded with a keynote on “Transforming Clinical Research Through Innovative Medicines,” highlighting Novo Nordisk’s commitment to revolutionizing clinical research.
This MOU represents a significant step forward in our joint efforts to advance clinical trials and patient care.